Chimerix Inc (STU:CXF)
€ 3.03 0.21 (7.45%) Market Cap: 298.58 Mil Enterprise Value: 168.48 Mil PE Ratio: 0 PB Ratio: 2.29 GF Score: 51/100

Chimerix Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 07:30PM GMT
Release Date Price: €1.33 (-3.97%)
Maury Raycroft
Jefferies - Analyst

Hi, everyone. My name is Maury Raycroft, and I'm one of the Biotech Analysts at Jefferies. I'm happy to introduce our guest today, Mike Sherman, President and CEO of Chimerix, and Mike Andriole, the CFO. This is going to be a fireside chat format. Thanks so much for joining us today.

Mike Sherman
Chimerix, Inc. - CEO

Thanks for having us, Maury.

Mike Andriole
Chimerix, Inc. - CFO and Chief Business Officer

Thanks, Maury.

Maury Raycroft
Jefferies - Analyst

And maybe to start off if -- for those who are new to the story, if you want to provide a one minute intro to Chimerix.

Mike Sherman
Chimerix, Inc. - CEO

Sure. Our most advanced program, ONC201 or dordaviprone is being developed in H3 K27M, so a genetically mutated patient population within glioma. The Phase 2 trial, which is the basis for advancing to that gave us a really good insight into definitive durable responses in the relapse

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot